CNBX

$0.00-50.00%visit website

CNBX Pharmaceuticals Inc.

Market Cap

$160,576.81

Live price × SEC shares (Jun 17, 2026)

Sector

Health Care

Industry

Pharmaceuticals

Beta (raw)

0.63

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to May 2026 · negative earnings

No 10-Q/10-K since Jun 24, 2026

P/S (TTM)

—

Mkt cap / TTM revenue

No 10-Q/10-K since Jun 24, 2026

P/B

N/M

TTM to May 2026 · negative equity

No 10-Q/10-K since Jun 24, 2026

EV/EBITDA (TTM)

—

EV / TTM EBITDA

No 10-Q/10-K since Jun 24, 2026

Loading…

Financial Statements

USD thousands	Q4 FY2025 Aug 31, 2025	Q1 FY2026 Nov 30, 2025	Q2 FY2026 Feb 28, 2026	Q3 FY2026 May 31, 2026	TTM May 31, 2026
Revenue	0.00	0.00	0.00	0.00	0.00
Cost of revenue			0.00	0.00
Gross profit			0.00	0.00
Research & development	0.00	0.00	0.00
Total operating expenses	130	64	73	163	429
Operating income	(130)	(64)	(73)	(163)	(429)
Interest expense	18.3	46.3	(32.6)
Net income	(150)	(114)	(44)	(154)	(462)
EPS (basic) ($)		0.00	0.00	0.00	—
EPS (diluted) ($)		0.00	0.00	0.00	—
Weighted avg. shares (basic)		732,857	931,016	1,318,594
Weighted avg. shares (diluted)		732,857	931,016	1,318,594

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Jun 24, 2026, period ended May 31, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 57 more quarters, back to Nov 2010, with Tormere Pro.

Corporate Events (8-K)

2 filings in 12 months · 1 with priority itemsFull history →

Filed	Items	Filing
Oct 1, 2026 accepted 6:09 PM ET	4.01Auditor change	Document SEC ↗
Mar 17, 2026 accepted 12:30 PM ET	1.01Material agreement	Document SEC ↗
Jan 30, 2025 accepted 12:12 AM ET	1.01Material agreement	Document SEC ↗